Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.

ABSTRACT: Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.

SUBMITTER: Kuma Y 

PROVIDER: S-EPMC12530469 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature